Corporate ActionApr 30, 2026, 04:38 PM
NTLA Raises $194.6M in Public Offering; Extends Cash Runway
AI Summary
Intellia Therapeutics, Inc. completed a public offering of 16,744,187 common shares at $10.75 per share, with underwriters fully exercising an option for an additional 2,511,628 shares. The offering generated approximately $194.6 million in net proceeds, which will be used to advance clinical development, prepare for commercial launch, fund R&D, and for potential acquisitions. The company expects these proceeds, combined with existing cash, to fund operations at least into 2028. Intellia also reported preliminary unaudited cash, cash equivalents, and marketable securities of approximately $517.2 million as of March 31, 2026.
Key Highlights
- Completed public offering of 16,744,187 common shares at $10.75 per share.
- Underwriters fully exercised option for 2,511,628 additional shares.
- Net proceeds from the offering totaled approximately $194.6 million.
- Proceeds to fund clinical development, commercial launch, R&D, and potential acquisitions.
- Company expects to fund operations at least into 2028 with new capital.
- Preliminary unaudited cash, cash equivalents, and marketable securities were $517.2 million as of March 31, 2026.
- Raised $33.6 million from an "at the market" offering in Q1 2026.